First clinical proof-of-concept that FMT can overcome resistance to ICIs
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pioneering studies in mice and melanoma patients have already demonstrated its safety and efficacy in improving anti-PD1 therapy,13,229,231,232,235 and additional studies and meta-analyses are investigating its mechanism of action.230,234”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [235]
In the citing paper
“Lastly, factors underlying the enterofecal compatibility code between donors and recipients are poorly understood (Elkrief and Routy, 2021).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Elkrief and Routy, 2021
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757 · cited 1×
“Baruch et al.(9) 10 patients with ICIrefractory metastatic melanoma 2 donors with melanoma and a CR to ICIs lasting >1 year; colonoscopy (1 ×), followed by oral capsules for 6 cycles 1 CR and 2 PRs (all among 5 patients with FMT from donor 1); no grade ≥2 irAEs Stronger clustering of postFMT microbiome with donor 1 vs…”
BackgroundThe gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523
Self-citationNovel patterns of response under immunotherapy
Borcoman, E., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P., & Le Tourneau, C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz003 · Cited by 514
Derosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.044 · Cited by 398
Self-citationHakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0196 · Cited by 316
Self-citationWilson, B. E., Routy, B., Nagrial, A., & Chin, V. T. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02453-2 · Cited by 152
Self-citationDaillère, R., Routy, B., Goubet, A., Cogdill, A. P., Ferrere, G., Silva, C. A.-C., Fluckiger, A., Ly, P., Haddad, Y., Pizzato, E., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1794423 · Cited by 17
Self-citation
Cited by
The coming decade in precision oncology: six riddles
Wahida, A., Buschhorn, L., Fröhling, S., Jost, P. J., Schneeweiss, A., Lichter, P., & Kurzrock, R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00529-3 · Cited by 205
“Today, the importance of the microbiota for the efficacy of immunotherapy has been increasingly accepted 99 , and the therapeutic effect of restoring a beneficial microbiota has been suggested in seminal trials 100–102 .”
Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04186-5 · Cited by 123
“Subsequently, two phase 1 clinical trials demonstrated the first proof of concept that FMT from patients with response to anti-PD-1 could overcome primary or acquired resistance to ICI 20–22 .”
Self-citationElkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 107
“…there may be a theoretical advantage to replacing cancer-associated dysbiosis with the microbiome from a healthy person, characterized by high bacterial diversity and beneficial bacteria, and, in the future, being able to select the donor with the most compatible microbiome composition 83 .”
Self-citationGang, X., Yan, J., Li, X., Shi, S., Xu, L., Liu, R. M., Cai, L., Li, H., & Zhao, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217241 · Cited by 80
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
“These two studies also became the first clinical proof-of-concept studies showing that FMT overcomes ICB resistance [172], which greatly expanded the prospects of the clinical application of FMT in antitumor immunotherapy strategies.”
Result
Metadata
- Authors
- Elkrief, A., & Routy, B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Routy, Bertrand
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-03-19
- Volume
- 18
- Issue
- 6
- Pages
- 325-326
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3136398125
- Cited by
- 23
- References
- 10
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 2 · 2021: 2
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- fecal microbiota transplantation, immune checkpoint inhibitors, anti-PD-1, melanoma, gut microbiota, treatment resistance, cancer immunotherapy
- MeSH terms
- Humans, Immunotherapy, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First clinical proof-of-concept that FMT can overcome resistance to ICIs. https://app.cochat.ai/papers/10.1038/s41571-021-00502-3
- The paper
- Elkrief, A., & Routy, B. (2021). First clinical proof-of-concept that FMT can overcome resistance to ICIs. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-021-00502-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.